Studer Jacqueline 4
4 · IDEXX LABORATORIES INC /DE · Filed Feb 27, 2019
Insider Transaction Report
Form 4
Studer Jacqueline
CVP, Gen. Counsel & Secretary
Transactions
- Sale
Common Stock
2019-02-25$211.70/sh−1,223$258,907→ 5,695 total - Exercise/Conversion
Common Stock
2019-02-25$79.54/sh+1,156$91,948→ 6,918 total - Sale
Common Stock
2019-02-25$212.05/sh−472$100,089→ 5,223 total - Sale
Common Stock
2019-02-26$208.06/sh−834$173,523→ 4,389 total - Exercise/Conversion
Incentive Stock Option (right-to-buy)
2019-02-25−1,156→ 708 totalExercise: $79.54Exp: 2025-02-13→ Common Stock (1,156 underlying)
Footnotes (4)
- [F1]Represents the weighted average sales price of the shares sold ranging from a low of $211.00 to a high of $211.96 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F2]Represents the weighted average sales price of the shares sold ranging from a low of $208.00 to a high of $208.23 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F3]Grant of option to buy 3,140 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- [F4]Not applicable.